- Home
- FUN vs ANAB Comparison
FUN vs ANAB Comparison
Compare FUN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUN | ANAB |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FUN | ANAB |
|---|---|---|
| Price | $15.54 | $62.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $27.08 | ★ $68.10 |
| AVG Volume (30 Days) | ★ 1.7M | 477.1K |
| Earning Date | 05-25-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,100,289,000.00 | $234,603,000.00 |
| Revenue This Year | $4.64 | N/A |
| Revenue Next Year | $3.88 | $43.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 14.45 | ★ 157.01 |
| 52 Week Low | $12.51 | $15.32 |
| 52 Week High | $39.21 | $66.66 |
Technical Indicators
Market Signals| Indicator | FUN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 64.94 |
| Support Level | $14.70 | $43.67 |
| Resistance Level | $16.08 | N/A |
| Average True Range (ATR) | 0.96 | 3.68 |
| MACD | -0.19 | 0.69 |
| Stochastic Oscillator | 13.39 | 77.18 |
Price Performance
Historical ComparisonAbout FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).